NYSE · DOLE
Dole plc
$13.00-$0.15 (-1.14%)
Dole plc’s quoted price sits in the lower half of its reported 52-week range, 21.54% below the high.
Loading market information…
NASDAQ · LHDX · USD
Stock price, earnings
Quote as of Mar 3, 2023, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Lucira Health, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.6% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Lucira Health, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Lucira Health, Inc. is a medical technology enterprise dedicated to the development and commercialization of diagnostic test kits for infectious diseases. The company has innovated a platform capable of providing molecular testing capabilities. Among its current product offerings is the LUCIRA COVID-19 All-In-One Test Kit, and it is also progressing with the development of diagnostic solutions for influenza A and B viruses. Lucira Health holds a patent license agreement with Eiken Chemical Co., Ltd., alongside technical and manufacturing service agreements with Jabil, Inc. and Jabil MSA, respectively. Founded in 2013, the company operated as DiAssess Inc. until January 2020 when it rebranded to Lucira Health, Inc. Its main offices are situated in Emeryville, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:19 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Aug 12, 2021 |
| -$0.38-18.75% vs estimate |
| $12.44M+55.49% vs estimate |
| Q1 2021 | May 13, 2021 | -$0.54-63.64% vs estimate | $4.52M+11.11% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$13.00-$0.15 (-1.14%)
Dole plc’s quoted price sits in the lower half of its reported 52-week range, 21.54% below the high.
$0.84+$0.03 (+3.12%)
Elutia Inc’s quoted price sits in the lower half of its reported 52-week range, 39.64% below the high.
$0.70-$0.00 (-0.16%)
Enzo Biochem, Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.27% below the high.
$13.60-$2.51 (-15.58%)
Pieris Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.07% below the high.
$2.27+$0.01 (+0.44%)
Conformis, Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.69% below the high.
$0.46+$0.00 (+0.22%)
Chembio Diagnostics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.31% below the high.
$0.14$0.00 (0.0%)
Titan Medical Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.33% below the high.
$1.15-$0.04 (-3.36%)
MetaVia Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.26% below the high.
